Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.

News Market Reaction

-3.13% 1.8x vol

14 alerts

-3.13% News Effect

-55.8% Trough in 9 hr 7 min

-$8M Valuation Impact

$254M Market Cap

1.8x Rel. Volume

On the day this news was published, ELDN declined 3.13%, reflecting a moderate negative market reaction. Argus tracked a trough of -55.8% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $254M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025, at 10:30 a.m. ET (7:30 a.m. PT).

To register in advance for the webcast, sign up here.

A webcast replay will be accessible following the live session on the Company’s website under Events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When will Eledon Pharmaceuticals (ELDN) present at the Guggenheim Healthcare Innovation Conference?

Eledon will present on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT).

Who from Eledon (ELDN) will present at the November 12, 2025 Guggenheim conference?

David-Alexandre C. Gros, M.D., Chief Executive Officer, will present.

How can investors watch Eledon (ELDN) present on November 12, 2025?

Investors can register for the live webcast in advance and view a replay on Eledon's website under Events.

Will a replay of Eledon’s (ELDN) Guggenheim presentation be available after November 12, 2025?

Yes. A webcast replay will be accessible following the live session on the company website under Events.

Where can I register to watch Eledon (ELDN) at the Guggenheim Healthcare Innovation Conference?

Register in advance via the webcast sign-up link provided by the company; the live session details are for November 12, 2025 at 10:30 a.m. ET.